NCT05631288

Brief Summary

A significant influence of the Herpes viruses family in the progression of periodontal disease has been suggested. The aim of this study was to investigate the potential association of four Herpes viruses (HSV-1, HSV-2, CMV and EBV) with periodontal disease using a qualitative test for evaluating the presence or absence of viral DNA in crevicular fluid samples of both healthy periodontal patients and periodontal compromised patients. Adult patients with healthy periodontium or periodontally compromised attending the Egas Moniz university dental clinic (Almada, Portugal) are eligible to participate The study involves a periodontal diagnosis and collection of unstimulated crevicular fluid from saliva samples. There will be no direct benefits for patients, but indirect benefit of advancing science in the study of potential involvment of Herpes viruses in periodontitis. No risks of participating are antecipated as the study material and data will be anonymized. The study runs from the the Cooperativa de Ensino Egas Moniz and is expected to run for 3 months.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Mar 2019

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2019

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 31, 2019

Completed
2.5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2022

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

November 21, 2022

Completed
9 days until next milestone

First Posted

Study publicly available on registry

November 30, 2022

Completed
Last Updated

November 30, 2022

Status Verified

November 1, 2022

Enrollment Period

5 months

First QC Date

November 21, 2022

Last Update Submit

November 21, 2022

Conditions

Keywords

periodontitisherpes virus

Outcome Measures

Primary Outcomes (1)

  • The presence of virus DNA (HSV1, HSV2, EBV and CMV)

    The presence of virus DNA (HSV1, HSV2, EBV and CMV)

    1 day

Secondary Outcomes (3)

  • Smoking

    one year

  • Alcohol consumption

    one year

  • Oral hygiene habits

    one year

Study Arms (2)

Cases

Periodontally compromised patients attending the Periodontology Department during periodontal diagnosis appointments at the point of first diagnosis.

Genetic: Sampe collection

Controls

Periodontally healthy patients attending the remaining specialty departments ath the same clinic at the point of first diagnosis.

Genetic: Sampe collection

Interventions

Unstimulated crevicular fluid samples are collected using two sized 35 paper cones per subject, both used in the sampling process. The DNA is extracted from the samples through multiplex PCR at the Egas Moniz Applied Microbiology Laboratory (LMAEM).

CasesControls

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients (\> 18 years of age) with natural teeth present attending clinical appointments at the Egas Moniz university dental clinic.

You may qualify if:

  • Patients (\> 18 years of age) with natural teeth attending clinical appointments at the Egas Moniz university dental clinic;
  • Cases (periodontally compromised) included at the Department of Periodontology of the same clinic;
  • Controls (periodontally healthy) included at the remaining departments of the same clinic.

You may not qualify if:

  • Occurrence of a viral infection during the six months prior to the clinical study;
  • Exposure to antiviral medication in the six months prior to the survey;
  • Clinical history of immunosuppression, either exogenous or endogenous;
  • Chemotherapy in the previous six months.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Malo Clinic

Lisbon, 1600-042, Portugal

Location

Biospecimen

Retention: SAMPLES WITH DNA

Unstimulated crevicular fluid samples

MeSH Terms

Conditions

Periodontitis

Condition Hierarchy (Ancestors)

Periodontal DiseasesMouth DiseasesStomatognathic Diseases

Study Officials

  • Miguel A de Araújo Nobre, PhD

    Maló Clinic

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
PhD

Study Record Dates

First Submitted

November 21, 2022

First Posted

November 30, 2022

Study Start

March 1, 2019

Primary Completion

July 31, 2019

Study Completion

February 1, 2022

Last Updated

November 30, 2022

Record last verified: 2022-11

Data Sharing

IPD Sharing
Will share

he datasets generated during and/or analysed during the current study will be available upon reasonable request.

Time Frame
8 years
Access Criteria
Upon reasonable request

Locations